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Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular
disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such
OPG has emerged as a potential biomarker for CVD. This review focuses on the relationship between circulating OPG and
different endocrine cardiometabolic alterations such as type 1 and 2 diabetes. The association of OPG with diabetic complications
(neuropathy, nephropathy, or retinopathy) as well as with atherosclerosis, coronary artery calcification, morbidity, and mortality
is pointed out. Moreover, OPG modulation by different treatments is also established. Besides, other associated diseases such as
obesity, hypertension, and metabolic syndrome, which are known cardiovascular risk factors, are also considered.
1. Osteoprotegerin: Discovery and Structure
Osteoprotegerin (OPG)was first identified in 1997 simultane-
ously by two different research groups. Simonet et al. (1997)
[1] were involved in a foetal rat intestine complementary
deoxyribonucleic acid- (cDNA-) sequencing project when
they discovered a new possible member of the tumour
necrosis factor (TNF) receptor superfamily. It was named
OPGbecause of its protective effects in bone (Latin: “os” bone
and “protegere” to protect).
At the same time, another research group, Tsuda et
al. [2], found a novel binding protein with no homology
to known proteins in the conditioned medium of human
embryonic lung fibroblasts which inhibited osteoclastogen-
esis. They termed this protein osteoclastogenesis inhibitory
factor (OCIF). A year later, Yasuda et al. [3] published that
these independent findings referred to the same molecule.
OPG/OCIF is a cytokine of the tumour necrosis factor
(TNF) receptor superfamily [4], also termed as TNF receptor
superfamily member 11B (TNFRS11B), and tropine reductase
1 [5]. The American Society of Bone and Mineral Research
Committee has decided to use the term OPG as it implies its
bone protective characteristics [6].
TheOPGgene identified and cloned in 1998 [7] is a single-
copy gene cluster on chromosome 8 (8q24) and it consists of
five exons over 29 kilo bases (Kb) [8]. Northern blot analysis
using a full-length cDNA probe produced three messenger
ribonucleic acid (mRNA) transcripts of 2.4, 4.2, and 6.5 Kb
[3]. The band at 2.4 Kb constituting the major transcript and
the two other transcripts represent alternatively spliced forms
containing all or a portion of the second intron that encodes
for a soluble molecule [9].
Biochemically, OPG is a basic secretory glycoprotein
composed of 401 aminoacids (Aa) that gives a monomeric
weight of 60 kilodaltons (kDa). It has seven structural
domains.
(i) Domains 1–4: four cysteine rich pseudorepeats struc-
turally related to the TNF receptor family located in
the N-terminal that is essential for the inhibition of
osteoclastogenesis.
(ii) Domains 5-6: two death domains at the carboxy-
terminal end of the protein contain apoptosis-
mediating death domain homologous regions.
(iii) Domain 7: a heparin binding site is located in the C-
terminal, capable of interacting with numerous pro-
teoglycans as well as a free cysteine residue required
for disulphide bond formation and dimerization [10,
11].
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Table 1: Osteoprotegerin expression and regulation in different tissues.
Cell type OPG expression Cytokine Reference
Osteoblasts
Upregulation
IL-1𝛼, IL-6, IL-11, IL-18, TNF-𝛼, bone morphogenic protein type 2
(BMP-2), calcium, vitamin D3, estrogens, angiotensin II and
platelet derived growth factor (PDGF), TNF-𝛽, IL-1𝛽, transforming
growth factor 𝛽 (TGF-𝛽), 17-estradiol and Wnt signalling pathway
[5, 119]
Dowregulation
Parathyroid hormone (PTH), glucocorticoids, prostaglandin E2,
calcium, immunosuppressant drugs, peroxisome proliferators
activated receptor (PPAR-𝛾), basic fibroblast growth factor (bFGF)
[5, 119]
Endothelial
Cells Upregulation IL-1𝛼, IL-1𝛽 and TNF-𝛼 [16]
Smooth Muscle
Cells
Upregulation
Dowregulation
IL-1𝛽, TNF-𝛼, estrogen and PDGF
TGF-𝛽 and BMP-2 [14]
Bone Marrow
Stromal Cells
Upregulation
Dowregulation
IL-18, TNF-𝛼, BMP-4 and TGF-𝛽
IGF-1, IL-6, IL-11, IL-17 and IL-1 𝛽 [5, 119]
Dendritic Cells Upregulation TNF-𝛼, RANKL, IL-1 𝛽 and CD40 ligand [5, 119]
Megakariocytes [17]
Adipose Tissue UpregulationDowregulation
IL1-𝛽 and TNF-𝛼
Cortisol or troglitazone [19, 76–78]
Other tissues: heart, kidney, liver, spleen, lung, thymus, lymph nodes, B-lymphocytes, articular
chondrocytes, trachea and testis.
Very low levels in brain, placenta and skeletal muscle
[5, 8, 13]
In addition to its monomeric structure, OPG can be assem-
bled at the cysteine 400 residue in the heparin binding
domain to form a disulphide-linked dimer. Prior to secretion
of both the monomeric and dimeric forms of OPG, the 21 Aa
signal peptide is cleaved from the N-terminal rendering a
380Aa mature OPG protein [12] (Figure 1). Thus, while the
OPG monomer is biologically active, OPG homodimer form
is more active and its formation is required to elicit full bio-
logical activity in vitro and in vivo [4, 9] because it possesses
higher affinity for the receptor activator of nuclear factor-𝜅𝛽
(RANKL) ectodomain than the OPGmonomer [11]. Tumour
necrosis factor-related apoptosis-inducing ligand (TRAIL)
and RANKL bind to OPG with similar affinities and they
share common residues on OPG for their interaction [11].
OPG was initially described as an antiresorptive cytokine
by binding principally to RANKL. However, since then,
numerous ligands were described and studied giving OPG
an increasing interest in vascular, tumour, and immune
biology [11]. Clinical outcomes confirm that OPG is an active
cytokine with potential use as a biomarker in a wide range
of pathologies (osteoporosis, arthritis, vascular calcification,
cancer bone-related disease, and so on) [11].
OPG is highly expressed in many different cell types
such as osteoblasts, heart, kidney, liver, spleen, bone marrow
[13], lung, thymus, lymph nodes, B-lymphocytes, articular
chondrocytes [5], trachea, and testis. However, it is detected
at very low levels in brain, placenta, and skeletal muscle [8].
In vitro studies indicate that OPG is expressed in cells
involved in atheroma plaque development and progression,
such as arterial smooth muscle cells [14] and pulmonary
artery smooth muscle cells [15], in the Weibel-Palade bodies
in endothelial cells [16] associatedwith von-Willebrand factor
and in megakaryocytes [17] in the alpha granules. Moreover,
OPG expression is enhanced in explanted human carotid
atherosclerotic plaques [18]. Furthermore, OPG expression
has recently been confirmed in human adipose tissue [19]
(Table 1).
2. OPG/RANK/RANKL Pathway
The receptor activator of nuclear factor-𝜅𝛽 (RANK), another
member of the TNF receptor superfamily, is a type I
homotrimeric transmembrane protein consisting of 616Aa
including a signal peptide (28Aa) with a 383-acid intracel-
lular domain, a short transmembrane domain of 21 Aa, and a
large C-terminal cytoplasmic domain [20, 21].
It is expressed on osteoclast precursors, mature osteo-
clasts, dendritic cells, B andT cells, fibroblasts, articular chon-
drocytes, and some cancer cells including breast and prostate
cancers, tumours with very high bone metastasis potential
[13]. After binding its ligand (RANKL), RANKassembles into
functional trimeric receptor and this trimerization is required
to generate multiple intracellular signals that regulate cell
differentiation, function, and survival, among the other
functional osteoclasts [22].
Receptor activator of nuclear factor-𝜅𝛽 ligand (RANKL)
belongs also to the TNF superfamily and it is a type II
homotrimeric glycoprotein consisting of 316Aa, which exists
as a transmembrane protein (40 to 45KDa cellular form)
and in a soluble form (31 KDa) [20]. Typically, RANKL is
expressed and secreted by osteoblasts [5]. RANKL is also
expressed in activated T-lymphocytes, lymph nodes, thymus,
mammary glands, lungs, spleen, and bone marrow [13].
While OPG presents as a soluble bone protector, RANKL
is considered to be a stimulator of bone resorption through
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Figure 1: Osteoprotegerin structure and different ELISA kit standards.
the induction of osteoclasts’ differentiation and activation of
mature osteoclasts [22].
OPG seems also to play a key role on cell survival, via
its interaction with tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL), anothermember of the TNF super-
family. TRAIL functions as a homotrimer and it is expressed
as a type II transmembrane protein.The extracellular domain
of this protein is proteolytically cleaved from the cell surface
to act as a soluble cytokine [4].
Classically, the OPG/RANK/RANKL network is involved
in bone remodelling and regulates the differentiation and
activation of osteoclasts and hence the critical balance
between bone formation and bone resorption. RANKL binds
to RANK on osteoprogenitor cells and controls osteoclasto-
genesis and bone resorption. Initially, this RANKL-RANK
interaction leads to the activation of nuclear factor-𝜅𝛽
that occurs by degradation of I𝜅B protein by I𝜅B kinase.
This degradation of I𝜅B protein frees the nuclear factor-𝜅B
complex, which then translocates to the nucleus initiating
intracellular signalling cascades that lead to transcription of
specific genes leading to osteoclast formation, differentiation,
activation, and consequently bone resorption. OPG acts as a
soluble decoy receptor, negatively regulating this interaction,
and competes with RANK, inhibiting RANKL-RANK inter-
actions [4, 23–26] (Figure 2).
3. Osteoprotegerin in Clinical Studies
Although OPG has traditionally been implicated in bone
remodelling and it has been determined as a biomarker
in osteoporosis, the aim of this review is to highlight the
association of OPG to other pathologies such as diabetes
types 1 and 2, obesity, metabolic syndrome, or hypertension
(Figure 3).
3.1. Diabetes Mellitus. In an animal model, Vaccarezza et
al. [27] examined mRNA and protein OPG expression in
control and streptozotocin-induced diabetic rats at early time
points after the induction of diabetes. Diabetic rats showed
a rapid and significant increase of the steady-state mRNA
and protein levels of OPG in the aortic wall compared to
control animals. Thus, an abnormal elevation of OPG in the
vessel wall characterizes the early onset of diabetes mellitus
and might represent a molecular mechanism involved in the
vascular dysfunction characterizing this disease.
Different studies have shown that OPG levels are ele-
vated in patients with type 1 diabetes mellitus (Table 2).
Furthermore, prepubertal children with type 1 diabetes have
significantly increased OPG levels [28]. Besides, Xiang et al.
[29] also observed increasedOPG in these patients. However,
the study by Singh et al. showed opposite results in 35 patients
with type 1DM and in 25 age-, sex-, and ethnicity-matched
healthy controls. Serum OPG levels were significantly lower
in patients with type 1DM compared to normal controls
whereas RANKL levels were similar in both groups [30].
Different studies in type 1 diabetic cohorts have analysed
the association between OPG and diabetic complications
such as diabetic nephropathy [31–33] and neuropathy [34].
OPG is associated with poor glycaemic control and car-
diovascular disease (CVD) in patients with type 1 diabetes,
compatible with the hypothesis that OPG is associated with
the development of diabetic vascular complications [31].
Besides, in another cohort of type 1 diabetic patients, not only
OPG was elevated in patients with nephropathy but it also
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Figure 3: Summary of osteoprotegerin involvement in different endocrinological pathologies including diabetes, hypertension, obesity, and
metabolic syndrome.
gradually increased with the severity (OPG levels were sig-
nificantly elevated in patients with macroalbuminuria com-
pared to microalbuminuria as compared with patients with
normoalbuminuria and control subjects) [33]. This study
highlighted the association between OPG and the presence
and the severity of diabetic nephropathy. Besides, plasma
OPG significantly correlated to peripheral neuropathy in type
1DM, although differences in concentrations between both
groups did not reach significance [34].
In addition to diabetic complications, OPG levels have
also been associated with an increased risk of cardiovascular
events as well as mortality [35–37]. In type 1DM patients,
OPG was associated with silent myocardial ischemia after
correcting for other variables. The association of OPG with
silent myocardial ischemia was observed in both genders, in
type 1 and type 2 diabetic patients, in patients with or without
nephropathy, and in patients without but not with peripheral
arterial disease [37]. In a population study, OPG predicted
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Table 2: Studies assessing the association between osteoprotegerin and diabetes mellitus type 1.
Author, Date Population Findings
Xiang et al., 2007 [29] 22 newly diagnosed type 1 DM28 healthy subjects
Plasma OPG levels are elevated in newly diagnosed
type 1 DM
Singh et al., 2010 [30] 35 type 1 DM25 sex, age, ethnicity matched controls
Serum OPG levels were significantly lower in
patients with type 1 DM compared to normal
controls.
Rasmussen et al., 2006 [31] 199 type 1 DM without diabetic nephropathy192 type 1 DM with diabetic nephropathy
OPG associated with cardiovascular disease and
glycaemic control
Grauslund et al., 2010 [32] Population-based Fyn County Denmark200 type 1 DM long diabetes duration OPG associated with higher risk of nephropathy
Wang et al., 2013 [33] 80 type 1 DM30 controls
OPG associated with the presence and severity of
nephropathy
Nybo et al., 2010 [34] 200 type 1 DM305 type 2 DM OPG correlated with diabetic neuropathy
Avignon et al., 2007 [37] 465 diabetic patients with one additional risk factor OPG is associated with silent myocardial ischemia
Gordin et al., 2013 [35] 1,939 adults (population FinnDiane)Finnish Diabetic Nephropathy Study
OPG predicted an incident cardiovascular event and
peripheral vascular disease
Follow-up 10.4 years
Jorsal et al., 2008 [36] 397 type 1 DM overt nephropathy176 type 1 DM with persistent normoalbuminuria
OPG associated with mortality and renal
deterioration
Follow-up 11.3 years. Prospective observational study
an incident cardiovascular event and peripheral vascular
disease/amputation events during follow-up (10.4 years) [35].
Furthermore, OPG was associated with mortality as well as
with renal deterioration. Higher levels of OPG predicted all-
cause and cardiovascular mortality in patients with diabetic
nephropathy and deterioration of kidney function towards
end-stage renal disease [36].
Different studies have also been performed in type
2DM (Table 3) confirming that OPG levels were significantly
higher in these patients compared to healthy controls [38–
45]. Even after the exclusion of diabetic patients with a
history of micro- or macrovascular disease, OPG levels
remained significantly higher in diabetes [42] and in poorly
controlled diabetic patients, serum OPG levels are higher
than inwell-controlled diabetic patients [46].Moreover,OPG
levels were increased in plasma from type 2 diabetic patients
with microvascular complications [47, 48]. Furthermore,
the association of OPG and diabetic nephropathy was also
studied and OPG serum levels were significantly elevated
in patients with microalbuminuria and macroalbuminuria
as compared with patients with normoalbuminuria. In mul-
tivariate stepwise regression analysis, serum OPG has also
been shown to be an independent factor associated with the
severity of diabetic nephropathy [43]. Plasma OPG concen-
trations are significantly higher in type 2DM patients with
peripheral neuropathy [34], and serum and vitreous OPG
concentrations were demonstrated to be higher in diabetic
patients with retinopathy compared to those without [49].
In addition, plasmaOPG concentrations positively correlated
with diabetic neuropathy [44].
Type 2DM is associated with increased atherosclerosis,
with progressive vascular calcification being a major compli-
cation in the pathogenesis of this disease. Diabetic patients
had higher mean intima-media thickness (IMT), a surrogate
marker of atherosclerosis [50, 51], and OPG significantly
associated with IMT [39]. Multivariate analyses revealed that
the significant independent determinants of mean-IMT were
age, hypertension, osteopontin, and OPG [50].
An emerging regulatory pathway for vascular calcifica-
tion in diabetes involves the RANK, RANKL, and OPG [52].
Higher serum OPG levels are associated with higher preva-
lence of vascular calcification independently of progression
of diabetic nephropathy [51, 53, 54]. Serum OPG level has
also be demonstrated to be an independent predictor of
vascular calcification and progression [54]. Moreover, OPG
was significantly elevated in patients with increased coronary
artery calcification (CAC). In multivariable analyses, OPG
retained a strong association with elevated CAC scores after
adjustment for age, gender, and other risk factors [55, 56].
In logistic regression analysis (after adjustment for age and
main cardiovascular risk factors) serum OPG was associated
with increased risk of abnormal IMT, carotid plaque, aortic
calcification, and peripheral artery disease [51]. However, the
study by Bourron et al. [57] suggested that although there was
a significant association with OPG and calcification score in
univariate analysis, it was no longer significant inmultivariate
analysis. RANKL and OPG/RANKL were not significantly
associated with the calcification score.
Type 2DM and increased OPG levels are associated
with increased cardiovascular morbidity and mortality [52].
OPG was significantly associated with the presence [37]
and severity of silent myocardial ischemia after adjustment
for different risk factors [40]. There was an independent
association of OPG with asymptomatic coronary artery
disease in type 2DM [58, 59]. Furthermore, increased plasma
OPG concentration is associated with carotid and peripheral
arterial disease in type 2DM, whereas no relation is observed
with myocardial ischemia [60]. Moreover, OPG levels were
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Table 3: Studies assessing the association between osteoprotegerin and diabetes mellitus type 2.
Author, Date Population Findings
O’Sullivan et al., 2010 [42] 62 type 2 DM58 healthy subjects (age, gender, BMI) OPG is significantly increased in type 2 DM
Altinova et al., 2011 [46] 166 type 2 DM OPG levels are higher in poorly controlled DM
Yaturu et al., 2008 [41] 50 type 2 DM59 subjects without DM
OPG is elevated in type 2 DM and correlated with
insulin resistance. Cross-sectional study
Knudsen et al., 2003 [48] 80 subjects divided in four groupsaccording to glucose tolerance
OPG is increased in patients with microvascular
complications
Chang et al., 2011 [43] 179 type 2 DM OPG is associated with diabetic nephropathy
Xiang et al., 2007 [29] 154 newly diagnosed type 2 DM96 healthy controls
Plasma OPG levels are associated with urinary albumin
excretion
Nybo et al., 2010 [34] 200 type 1 DM305 type 2 DM
OPG is increased in patients with peripheral
neuropathy
Yu et al., 2015 [49]
254 diabetic patients (100 without
retinopathy, 154 with retinopathy), 62
controls
OPG is associated with retinopathy. Patients with
retinopathy exhibit increased vitreous and serum OPG
Terekeci et al., 2009 [44] 42 type 2 DM24 healthy controls OPG correlated with diabetic neuropathy
Tavintharan et al., 2014 [47] 1,220 type 2 DM
Higher OPG levels associated with microvascular
complications (nephropathy, neuropathy and
retinopathy)
Ishiyama et al., 2009 [50] 168 type 2 DM40 non-diabetic subjects
Diabetic patients had higher IMT and OPG was an
independent determinant of IMT
Moreno et al., 2013 [51] 68 males (43 with type 2 DM and 25subjects without diabetes)
Serum OPG associated with increased risk of abnormal
IMT, carotid plaque, aortic calcification and peripheral
disease
Gaudio et al., 2014 [39] 40 type 2 DM postmenopausal women40 healthy controls
OPG associated with IMT
Singh et al., 2012 [54] 58 type 2 DM OPG was an independent predictor of baseline vascularcalcification and progression
Anand et al., 2006 [55] 510 type 2 DM OPG is elevated in patients with CAC
Anand et al., 2007 [56] 398 type 2 DM OPG associated with elevated CAC
Bourron et al., 2014 [57] 198 type 2 DM LnOPG associated with calcification score.Cross-sectional study
Avignon et al., 2007 [37] 645 diabetic patients with one additionalrisk factor
OPG associated with the presence of silent myocardial
ischemia
Guzel et al., 2013 [40] 45 type 2 DM33 healthy controls
OPG associated with the presence and severity of silent
myocardial ischemia
Reinhard et al., 2011 [58] 200 asymptomatic DM patients withoutknown cardiac disease
OPG independently associated with asymptomatic
coronary artery disease
Avignon et al., 2005 [59] 162 asymptomatic type 2 DM OPG independently associated with asymptomaticcoronary artery disease
Poulsen et al., 2011 [60] 305 type 2 DM without knowncardiovascular disease
Increased plasma OPG associated with carotid and
peripheral arterial disease. No association with
myocardial ischemia
Bla´zquez-Medela et al., 2012 [38] 52 type 2 patients54 healthy controls
Higher OPG levels were observed in patients with
higher probability of 10-year cardiovascular risk
Reinhard et al., 2010 [61] 238 type 2 DM
Elevated plasma OPG was a strong predictor of
all-cause mortality. Follow-up 16.8 years. Prospective
observational study
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also higher in patients with high 10-year cardiovascular risk,
patients with three or more damaged target organs, and
patients with previous episodes of ischaemic cardiomyopathy
or hypercholesterolaemia [38]. In a prospective observational
follow-up study, elevated plasma OPG was a strong and
independent predictor of all-cause mortality [61].
3.2. Osteoprotegerin in Insulin Resistance. Several studies
have focused on the relationship between OPG and insulin
resistance assessed by the homeostatic model assessment for
insulin resistance (HOMA-IR). Yaturu et al. showed that
OPG levels significantly correlated with insulin and insulin
resistance [41]. Besides, O’Sullivan et al. [62] tested after a 75 g
oral glucose tolerance test andOPGwas higher in individuals
with abnormal glucose tolerance but OPG did not correlate
with HOMA-IR. Moreover, Hofsø et al. [63] demonstrated
that oral glucose suppressed OPG levels, independently of
obesity and glucose tolerance status indicating that glucose
may be involved in the acute regulation of these proteins.
Furthermore, the effect of acute hyperglycaemia on plasma
levels of OPG in nondiabetic subjects was also studied. Acute
hyperglycaemia increased plasma levels of OPG in non-
diabetic subjects, whereas hyperinsulinaemia may suppress
plasma OPG levels [64]. This observation is in accordance
with Secchiero et al. [65] that showed that high glucose
concentrations added to vascular endothelial cells did not
modulateOPG release when used alone or in associationwith
TNF-alpha.
Furthermore, insulin resistance and OPG levels have
also been studied in obese individuals. Jorgensen et al.
[66] studied the acute effects of insulin on plasma OPG
in type 2 diabetic patients and obese individuals compared
to lean controls. All subjects underwent a 4 h euglycemic-
hyperinsulinemic clamp. Acute hyperinsulinemia decreased
plasma OPG, but with diminished effect in individuals with
type 2DM and obesity. Besides, in obese adolescents, OPG
levels and HOMA-IR index were significantly higher than
in healthy volunteers and a significant positive correlation
between OPG and insulin resistance was found [67]. How-
ever, in premenopausal obese and normal weight women the
relationship between OPG and HOMA-IR was also assessed.
Circulating OPG levels showed a negative and significant
correlation with insulin and HOMA-IR [68].
In different healthy subjects (obese, overweight, or lean),
OPG levels were negatively correlatedwith bodyweight, BMI,
waist circumference, HOMA-IR, and fasting plasma insulin
while being positively correlated with insulin sensitivity [69].
Ugur-Altun et al. [70] pointed out that insulin resistance
in obesity is associated with decreased serum OPG levels.
Moreover, a significant negative correlation was observed
between OPG levels corrected for BMI and glucose, and
insulin and HOMA-IR.
3.3. Obesity and Adipose Tissue. In the literature there is
scarce and contradictory information regarding the rela-
tionship between OPG and obesity. Holecki et al. in obese
perimenopausal womenwith concomitant diseases and obese
general population found that serum OPG was significantly
lower in comparison to normal weight controls [71]. How-
ever, Suliburska et al. [67] showed that serumOPG levelswere
significantly higher in obese adolescents than in controls.
Furthermore, in a study by our group obese subjects exhibited
increased OPG concentrations compared to nonobese sub-
jects [19].
Abdominal adipose tissue is the largest fat tissue depot
in the body and correlates with CV disease risk, MS, and
other systemic inflammatory markers and may have an
effect on atherosclerosis [72]. Adipose tissue releases several
adipokines but also there is increasing evidence that there
is a hormonal cross-link between adipose tissue and bone
[73–75]. Interestingly, OPG expression has been recently
confirmed in adipose tissue [19, 76–78]. In 2007, An et al. [76]
described an increase in OPG expression during the differ-
entiation process of 3T3L1, while there were no differences
in RANKL expression. Besides, a higher OPG/RANKL ratio
was observed after stimulation with TNF-𝛼 and a decrease
in that ratio when cells were stimulated with insulin and
rosiglitazone. Afterwards, Harsløf et al. [78] confirmed the
expression of cytokines derived from bone in the adipose
tissue including OPG. They observed an increased OPG
expressionwith proinflammatory cytokines such as IL-1𝛽 and
TNF-𝛼 and a reduced OPG expression when stimulated with
cortisol or troglitazone. Besides, Fain et al. [77] in explants
from human adipose tissue from obese women observed that
OPG was secreted by both fat and nonfat cells. Moreover,
Pe´rez de Ciriza et al. [19] confirmed increased OPG mRNA
expression in adipose tissue from patients with the metabolic
syndrome compared to healthy controls.
3.4. Metabolic Syndrome. The metabolic syndrome (MS)
is a cluster of cardiometabolic alterations that include the
presence of arterial hypertension, insulin resistance, dys-
lipemia, and abdominal obesity [79]. As explained before,
individual criteria included in the MS definition such as DM,
hypertension, and obesity have been shown to upregulate
OPG concentrations. In the literature, there is scarce and
contradictory information about the relationship between
OPG and MS. Akinci et al. [80] showed that women with
previous gestational DM (𝑛 = 46) developing MS had higher
OPG levels than those without MS and healthy controls (𝑛 =
30). Furthermore, these results were confirmed in a larger
cohort including 128 women with previous gestational DM
and 67 age-matched controls. SerumOPG levels were associ-
ated with obesity, insulin resistance, and IMT [81]. However
Nabipour et al. [82] did not find significant differences
between the mean serum OPG levels of postmenopausal
women with and without the MS. In a community-based
study, Dallmeier et al. [83] observed a significant association
between the MS and different inflammatory biomarkers
except for OPG.
Recently, several publications have pointed out the pos-
itive relationship between OPG and MS. Pe´rez de Ciriza et
al. [19] showed that OPG levels were significantly higher in
MS patients compared to patients without the syndrome.
Interestingly, OPG levels significantly and positively corre-
lated with the number of cardiovascular risk factors. Besides,
8 International Journal of Endocrinology
OPG expression in adipose tissue was confirmed and MS
patients expressed higher OPG mRNA levels compared to
those without. Bernardi et al. [84] concluded that OPG
was elevated in patients with the MS compared to controls.
Besides, in an animal model of MS (high-fat diet fed C57BL6
mice) they confirmed that OPG was elevated and that
delivery of this protein promoted systemic and adipose tis-
sue proinflammatory changes in association with metabolic
abnormalities. They suggested that OPGmay trigger adipose
tissue proinflammatory changes in MS and high-fat diet
induced obesity. Furthermore, in the study by Tavintharan et
al. [47] higher OPG levels were associated with risk of MS
and after adjusting for age, gender, ethnicity, glucose, and
microvascular complications,OPG remained an independent
predictor of MS.
3.5. Hypertension. OPG levels have also been related to
hypertension. Stępien´ et al. [85] showed that OPG levels were
significantly elevated in hypertensive subjects (𝑛 = 130) com-
pared to normotensives. Furthermore, multiple regression
analysis demonstrated that inflammation, age, and hyperten-
sion were predictors of increased OPG levels. Furthermore,
in a study by our group [19] OPG concentration was also
significantly higher in hypertensive subjects confirming the
results by Stepien. OPG levels were associated with increased
risk of coronary calcification in asymptomatic normotensive
individuals, and renal function significantly contributed to
this process in both hypertensive and normotensive subjects
[86].
Significant correlations were found between OPG levels
and age, height, glycaemia, systolic, diastolic, and pulse blood
pressure, pulsewave velocity, and left ventricular hypertrophy
in hypertensive patients. In hypertensive subjects, markers of
inflammation are elevated and the pressure of arterial blood
may stimulate the endothelium promoting the inflammatory
cascade and increasing OPG concentration. Increased OPG
concentrations were also reported in hypertensive patients
suffering from related complications [38]. The serum OPG
level is positively associated with arterial stiffness in hyper-
tensive patients. In addition, amultivariate logistic regression
analysis showed that age, diastolic blood pressure, and OPG
levels were independent predictors of arterial stiffness in the
hypertensive patients [87].
4. Polymorphisms of the
Osteoprotegerin Gene
Different single nucleotide polymorphisms (SNPs) known
to be associated with osteoporosis (T245G, T950C, and
G1181C) were evaluated in type 2DM to study whether
they contributed to CVD in these patients. The C allele
of the T950C polymorphism was independently associated
with higher risk of CVD in type 2DM. However, there was
no significant association between the T245G and G1181C
polymorphisms and CVD [88].
Besides, the association of diabetic retinopathy and two
different SNPs of the OPG gene, rs2073618 (located in exon
I) and rs3134069 (located in the promoter region), were also
studied. Logistic regression analysis demonstrated that the
carriers of the CC genotype had a 2.2 higher risk for diabetic
retinopathy than thosewith either theCGgenotype or theGG
genotype (codominant model for rs2073618). Furthermore,
the combined effect of SNPs on the diabetic retinopathy
was stronger than that of each SNP alone. These results
indicate that SNPs in the OPG gene may be involved in the
pathogenesis of diabetic retinopathy [89].
Finally, the association of rs2073617, rs2073618, and
rs3134069 SNPs and diabetic foot was evaluated. The A
allele of the rs2073617 polymorphism protected women in
variant AA versus AG against diabetic foot compared with
controls. Besides, in the rs2073618 polymorphism, theC allele
was a risk factor for diabetic foot. However, the rs3134069
polymorphism was not observed to be a risk factor for
diabetic foot [90].
Different SNPs are also related to blood pressure or
hypertension. In a large cohort of elderly men, the SNP,
rs11573901, was significantly associated with diastolic blood
pressure, after adjusting for other risk factors. Men with the
TC genotype had lower diastolic blood pressure than those
with the common CC variation. However, this SNP was not
associatedwith plasmaOPG in the population examined [91].
The SNP in the promoter region of OPG (T950C) was
associated with vascular morphology and function in healthy
individuals [92]. The SNP was then studied in another
larger population of patients with hypertension and left
ventricular hypertrophy. Hypertensive subjects with the CC
genotype showed significantly increased IMT compared to
those hypertensives with the TC and TT genotypes.The allele
distribution did not differ between hypertensive and control
individuals. This study showed that SNP in the promoter
region of OPG is associated with vascular morphology in
hypertensive subjects [93].
5. Therapeutic Interventions
That Modulate OPG
Several treatments are known to affect OPG concentrations
such as insulin, glitazones, and statins. OPG levels signifi-
cantly decreased in both type 1 [29] and type 2 [94] DM,
after six months of insulin treatment. Besides, in type 2DM
(𝑛 = 67), pioglitazone (15 mg/day, 𝑛 = 34) treatment
for six months decreased OPG levels significantly. However,
metformin treatment (1000 mg/day, 𝑛 = 33) for the same
time did not vary OPG concentration [95]. Furthermore,
in patients from the South Danish Diabetes Study (𝑛 =
371), rosiglitazone treatment for 2 years caused a significant
decrease in plasmaOPG concentrations while treatment with
metformin or insulin did not change OPG [96].
Furthermore, treatment of hypercholesterolemic type
2DM with different statins showed contradictory results.
Simvastatin reduced plasma OPG levels [97] while OPG was
increased after pravastatin [98] and lovastatin treatment [99].
Thewithdrawal of lovastatin decreased serumOPG level [99].
However, in patients that had never received statins
before, statins decreased OPG levels. Simvastatin [100]
and atorvastatin (20mg/day) [101] treatment significantly
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decreased serum levels of OPG. Besides, patients with hyper-
tension (𝑛 = 48) were treated with 20mg olmesartan
combined to 16mg azelnidipine or 1mg indapamide. Azel-
nidipine, but not indapamide, combined with olmesartan
improved arterial stiffness andwas associatedwith significant
decrease in OPG [102].
In addition to different treatment, other interventions
modulate OPG concentration. Weight reduction therapy
resulted in a further decrease in OPG serum concentrations
[103]. However, bariatric surgery did not modify OPG levels
although there was an improvement in other parameters
[104]. Besides, in overweight and obese patients undertaking
a 6-month exercise programme, OPG levels did not change
significantly [105].
6. Pathophysiological Role of Osteoprotegerin
Nowadays there is emerging evidence of the role of OPG in
the pathogenesis of atherosclerosis, calcification, and CVD.
Different studies have highlighted different potential mecha-
nisms that may explain the association. Evidence is accumu-
lating that OPGmay be expressed, be regulated, and function
in vascular physiology and pathology in unique ways to
promote endothelial cell survival, angiogenesis, monocyte,
or endothelial cell recruitment, and smooth muscle cell
osteogenesis, and calcification [106].
In endothelial cells,OPGacted as a survival and antiapop-
totic factor.OPGprotected endothelial cells fromapoptosis in
vitro and promoted neovascularization in vivo. Besides, OPG
increased endothelial cell proliferation in microvessels [107].
Moreover, OPG stimulated the expression of intercellular
adhesion molecule-1, vascular cell adhesion molecule-1, and
E-selectin by endothelial cells in the presence of TNF-alpha
[108]. Furthermore, emerging evidence suggests a role of
OPG in endothelial cell survival and treatment of endothelial
cells with proinflammatory cytokines, which secretedOPG to
the supernatant [16].
In addition to its effects on endothelial cells, OPG
increased the expression of adhesion molecules as well as
monocyte binding to endothelial cells [108]. Furthermore,
in an in vivo model, Zauli et al. [109] demonstrated that
leukocyte/endothelial cell adhesion and leukocyte rolling
was promoted by OPG. Moreover, in plaques from different
locations, OPG expression by stainingwas correlatedwith the
abundance of macrophages in the lesions [110].
In vascular smooth muscle cells, both in vitro and in
vivo treatments using OPG induced signs of fibrosis [111] and
inhibited vascular calcification [112]. Moreover, recombinant
OPG promoted vascular smooth muscle cells proliferation
in both human [15] and rodent cells [113]. All these findings
suggest that OPG may be involved in different processes that
lead to atherosclerosis and CVD (Figure 4).
In spite of this evidence of OPG as a proatherogenic
mediator and the association ofOPGwith atherosclerosis risk
factors, discussion still exists on the meaning of OPG as a
marker of a mediator of cardiovascular disease.
Some hypotheses suggest that the association of increased
OPG seen in cardiovascular disease is the result of an
incomplete compensatory mechanism. It is possible that
circulating OPG levels are increased in response to the initial
vascular insult and ongoing process of inflammation within
an atherosclerotic plaque lesion as the component of a com-
plex compensatory mechanism [4]. Indeed, recent evidence
suggests that damaged endothelial cells may release OPG
fromWeibel-Palade bodies in response to inflammation, thus
increasing circulating levels. Although vascular endothelial
cells may be the source of the circulating OPG with the onset
of atherosclerosis, it is not clear whether increased expression
is required for the changes in circulating levels [114]. Besides,
in diabetic patient, increased OPG production may represent
an early event in the natural history of diabetes mellitus,
possibly contributing to disease-associated endothelial cell
dysfunction [65].
However, different findings in animals [114] suggest that
endogenous OPG may be a marker, rather than a mediator,
of atherosclerosis. Furthermore, OPG elevation appears to be
a marker of atherosclerosis onset rather than its severity or
progression.
On the other hand, various studies highlight the apparent
proatherogenic role of increased OPG itself taking part in
different steps involved in the atherogenic process. It seems
that OPG plays a role in endothelial cell stimulation and
dysfunction [16, 108] as well as macrophage infiltration [110]
and leukocyte adhesion [109]. Moreover, OPG promotes
SMCs proliferation [15, 113]. Circulating OPG levels could
probably indicate ongoing EC injury as well as activation of
the SMCs, which have been observed in progressing plaque
lesions. An increased OPG level could be an indicator of
a proinflammatory milieu responsible for propagation of
atherosclerosis [4].
OPG would appear to have a dichotomous role in
humans. In healthy individuals, the proatherogenic and
antiatherogenic effects are being held in a fine balance, but
in the face of persistent positive induction by various risk
factors the proatherogenic pathway becomes predominant to
the detriment of the subject [4]. Besides, the role of OPG
differs between studies in humans and animals. Observa-
tional studies in humans show a positive relationship between
serumOPG levels and clinical cardiovascular diseasewhereas
animal studies support a protective role for OPG [114].
Thus,more research is required to elucidatewhetherOPG
is an ineffectivemarker ofCVDor if it represents a pathogenic
factor.
7. Osteoprotegerin as a Biomarker
OPG is highly expressed in both bone and vasculature.
Although several studies and different evidence suggest the
involvement of OPG in cardiovascular risk and cardiovascu-
lar disease, more evidence is needed to evaluate the predictive
and diagnostic value of serum OPG levels for clinical use as
well as its pathogenic importance [115].
In view of the association between OPG and different
cardiovascular risk factors in humans, there is significant
interest in developing OPG as a biomarker. Its clinical role
is limited due to the expression by numerous types of tissues
in vivo. Identifying tissue isoforms will potentially increase
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Figure 4: Pathological role of osteoprotegerin in endothelial cells, smooth muscle cells, and macrophages.
the clinical utility as a biomarker. Furthermore, OPG levels
measured in circulation correspond to the OPG monomer,
dimer, and bound OPG. As a result it is necessary to better
define and establish OPG measurement conditions and the
potential sources of variability.
In order to implement OPG as a biomarker in the
clinical laboratory setting, it is important to consider different
preanalytical and analytical variables that may influence its
measurement.
OPG is measured using a variety of ELISA kits with
different standards with different molecular weights resulting
in differences in the final OPG concentration as high-
lighted by Clancy et al. [116]. These variations appear largely
attributable to differences in the standards used. R&DDuoSet
standard is similar to full-length OPG suggesting that this
ELISA kit may be more representative of the OPG molecule
(Figure 1). Besides, as suggested by Naylor et al. [117] OPG
exists in different forms in serum, monomer, and dimmers,
and the cross-reactivity of available immunoassays to these
components is unknown.
Circulating OPG can be measured in both plasma and
serum. However, the resultant concentration is not compa-
rable due to the lower OPG levels observed in serum samples
and higher OPG levels in all plasma samples [118] including
EDTA [119]. Due to this, caution should be taken when
comparing OPG concentration from different studies due to
the differences observed among sample type and standards
used. Besides, each laboratory should determine adequate
reference ranges for each specimen. Furthermore, circulating
OPG reflects the production from several tissues, which
makes it difficult to specify the site of origin [120].
After blood collection, other steps such as transport,
delayed processing, centrifugation, or storage should be ad-
equately controlled. Increasing centrifugation forces do not
alter OPG concentration and serum separation after centrifu-
gation should be performed as soon as possible (within 30
minutes). Serum centrifuged samples are more stable and
they should preferably be stored at 4∘C for amaximumperiod
of 24 hours. Longer storage may be done at −20∘C [118] or
at −70∘C [119]. OPG concentration increased after several
freeze-thaw cycles [118, 121]; a maximum of three is suggested
in order to minimize this increase.
Although the clinical prognostic utility of OPG seems
to be awhile away yet, considering these recommendations,
OPG quantification may be more stable and reproducible.
Quantifying OPG holds a great deal of promise in helping
the clinician risk to stratify patients with cardiovascular
disease more accurately in combination with other markers
to provide clinically relevant information. However, more
research is necessary in order to better clarify the role of OPG
in cardiovascular disease.
8. Conclusion
OPG levels have been related to different cardiometabolic
alterations such as diabetes, obesity, hypertension, and
metabolic syndrome. Furthermore, increased OPG levels
associate with poor diabetes control, diabetic complications,
atherosclerosis, CAC, and mortality. As a result, OPG may
be a potential biomarker of complications and severity. How-
ever, more evidence is needed to evaluate the predictive and
diagnostic value of serum OPG levels for clinical use as well
as the possible mechanism involved in the increase observed.
Furthermore, implementation of OPG determination in the
clinical laboratory setting would be useful in order to better
stratify patients and to assess the most adequate treatment.
Nevertheless, more research and more evidence will be
needed in order fully assess OPG usefulness in the laboratory
as a biomarker.
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